“…FOXD3-AS1 has been shown to have predictive value and functional roles in various diseases, including breast cancer, cervical cancer, nasopharyngeal carcinoma, cerebral ischemia/reperfusion injury, cardiomyocyte injury, allergic rhinitis, and so on [ 15 – 17 , 27 , 28 ]. Furthermore, FOXD3-AS1 has been found in nuclear or cytoplasm fractions, and its molecular mechanisms include acting as competing endogenous RNA [ 15 , 29 ], acting as mediators for gene promotor loci and histone modification factor interaction [ 19 ], stimulating proteins expression [ 20 ], interacting and sequestering proteins, and so on [ 14 , 18 ]. In this study, we found that FOXD3-AS1 was upregulated in all primary subtypes of LC at an early stage and increased as the disease progressed.…”